Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2008

Executive Summary

Highlights from the Q4 2008 review of pharmaceutical and biotechnology dealmaking: Financing dollar volume was only one-fourth that of Q3 with 57 deals bringing in over $1.09 billion, with no IPOs or FOPOs, but early-stage VC rounds accounting for 41% of this total. M&A dollars also were down: $7.6 billion in Q4--versus the $25.2 billion of the previous quarter--and contributing just 15% to the category's 2008 annual total. Alliances saw the most activity, boasting ten deals with pre-commercialization values greater than $100 million. Five of those were over $275 million, including Bristol-Myers Squibb Inc.'s $850 million tie up with Exelixis Inc., not only the fourth quarter's highest, but the second-largest alliance of the year.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts